Status:
COMPLETED
Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022
Lead Sponsor:
Vastra Gotaland Region
Collaborating Sponsors:
Swedish Heart Lung Foundation
Göteborg University
Conditions:
Hypertension
OSA - Obstructive Sleep Apnea
Eligibility:
All Genders
18+ years
Brief Summary
Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failu...
Detailed Description
Please see attached analysis plan
Eligibility Criteria
Inclusion
- Adult patients starting PAP treatment for OSA in the swedevox registry between 2010-2021 with and without hypertension. Randomly selected controls with and without hypertension from the general population.
Exclusion
- Patients with manifest cardiovascular disease (stroke, ischemic heart disease, cardiac failure or atrial fibrillation at baseline).
- Patients with kidney failure at baseline.
- Patients with malignant cancer at baseline.
- Subjects with missing data on any of the main variables in the fitted models.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2025
Estimated Enrollment :
148467 Patients enrolled
Trial Details
Trial ID
NCT06930989
Start Date
January 1 2025
End Date
April 30 2025
Last Update
May 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sahlgrenska University Hospital and Göteborg University
Gothenburg, VGR, Sweden, 41390